CoQ10 and memory tests
What a study of ubiquinol and cognitive tests in adults aged 60 and over showed.
Key points
- In adults aged 60 and over, ubiquinol showed no convincing advantage over placebo in the overall memory test result over 90 days. This trial did not demonstrate a confirmed improvement in memory. [1] See the evidence 1
- In the study of adults aged 60 and over, no advantage in information processing speed was found either. The result does not support an expectation of marked improvement in speed on similar tasks. [1] See the evidence 1
Practical guide
Check the conclusions and whether they apply to your situation.
Memory and information processing speed were assessed separately.
Key points
Why these conclusions
Test results
Adults aged 60 and over took 200 mg of ubiquinol daily or placebo for 90 days. No convincing advantage in the overall memory test result or information processing speed was found; certainty in each outcome is low. [1]
In adults aged 60 and over, ubiquinol showed no convincing advantage in overall memory test result over 90 days.
| Parameter | Data |
|---|---|
| Result | In adults aged 60 and over, ubiquinol showed no convincing advantage in overall memory test result over 90 days. Difference −0.09 (95% CI −0.32 to +0.13). |
| Participants | 111 adults aged 60 and over randomized; memory assessed in 54 receiving ubiquinol and 44 receiving placebo. |
| Form | Oral ubiquinol, a form of CoQ10 |
| Dose | 200 mg/day |
| Dose basis | 200 mg/day |
| Comparator | placebo |
| Duration | 90 days |
| Confidence | 2/4: Precision: Exact confidence intervals allow a small difference in either direction. Consistency: No grounds for a separate downgrade. Applicability to the specified group: The study tested the stated form, participant group and outcome. Possible publication bias: No specific data for a separate downgrade. Study methods: Noticeable losses and unequal analysis across groups. |
| Evidence base | 1 trial; outcome from the same participant group |
| Sources | [1] |
Ubiquinol showed no convincing advantage over placebo in information processing speed.
| Parameter | Data |
|---|---|
| Result | Ubiquinol showed no convincing advantage over placebo in information processing speed. −0.03 (95% CI −0.24 to +0.18). |
| Participants | 111 adults aged 60 and over allocated to groups; processing-speed outcome assessed in 48 receiving ubiquinol and 41 receiving placebo |
| Form | Oral ubiquinol |
| Dose | 200 mg/day |
| Dose basis | 200 mg/day |
| Comparator | placebo |
| Duration | 90 days |
| Confidence | 2/4: Precision: Exact confidence intervals allow a small difference in either direction. Consistency: No grounds for a separate downgrade. Applicability to the specified group: The study tested the stated form, participant group and outcome. Possible publication bias: No specific data for a separate downgrade. Study methods: Noticeable losses and unequal analysis across groups. |
| Evidence base | 1 trial; outcome from the same participant group |
| Sources | [1] |
More details
How to interpret results
The results apply to the studied form, age group and two sets of tests. [1]
Sources
- Effect of Ubiquinol on Cognitive Function, Blood Pressure, Arterial Stiffness, and Biomarkers of Oxidative Stress and Inflammation in the Elderly: A Randomized Trial. https://doi.org/10.3390/antiox15070806
Methodology: Subpages evidence-led supplement pipeline v1